Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Livongo Health

Nasdaq:LVGO
Snowflake Description

Flawless balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
LVGO
Nasdaq
$3B
Market Cap
  1. Home
  2. US
  3. Healthcare
Company description

Livongo Health, Inc. provides an integrated suite of solutions for the healthcare industry in North America. The last earnings update was 10 days ago. More info.


Add to Portfolio Compare Print
LVGO Share Price and Events
7 Day Returns
6.8%
NasdaqGS:LVGO
2.4%
US Healthcare Services
-4.1%
US Market
1 Year Returns
-
NasdaqGS:LVGO
16.3%
US Healthcare Services
-14.9%
US Market
LVGO Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Livongo Health (LVGO) 6.8% -5.5% 3.9% - - -
US Healthcare Services 2.4% -4.3% -2.4% 16.3% 61.9% 36.3%
US Market -4.1% -19.1% -23.4% -14.9% 3.5% 14.5%
1 Year Return vs Industry and Market
  • No trading data on LVGO.
  • No trading data on LVGO.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Livongo Health undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Livongo Health. This is due to cash flow or dividend data being unavailable. The share price is $26.13.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Livongo Health's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Livongo Health's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGS:LVGO PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-1.09
NasdaqGS:LVGO Share Price ** NasdaqGS (2020-04-02) in USD $26.13
United States of America Healthcare Services Industry PE Ratio Median Figure of 12 Publicly-Listed Healthcare Services Companies 39.64x
United States of America Market PE Ratio Median Figure of 2,944 Publicly-Listed Companies 12.5x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Livongo Health.

NasdaqGS:LVGO PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:LVGO Share Price ÷ EPS (both in USD)

= 26.13 ÷ -1.09

-24.04x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Livongo Health is loss making, we can't compare its value to the US Healthcare Services industry average.
  • Livongo Health is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Livongo Health's expected growth come at a high price?
Raw Data
NasdaqGS:LVGO PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -24.04x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts
22%per year
United States of America Healthcare Services Industry PEG Ratio Median Figure of 11 Publicly-Listed Healthcare Services Companies 3.11x
United States of America Market PEG Ratio Median Figure of 2,008 Publicly-Listed Companies 0.91x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Livongo Health, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Livongo Health's assets?
Raw Data
NasdaqGS:LVGO PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $5.32
NasdaqGS:LVGO Share Price * NasdaqGS (2020-04-02) in USD $26.13
United States of America Healthcare Services Industry PB Ratio Median Figure of 38 Publicly-Listed Healthcare Services Companies 3.36x
United States of America Market PB Ratio Median Figure of 5,142 Publicly-Listed Companies 1.22x
NasdaqGS:LVGO PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:LVGO Share Price ÷ Book Value per Share (both in USD)

= 26.13 ÷ 5.32

4.91x

* Primary Listing of Livongo Health.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Livongo Health is overvalued based on assets compared to the US Healthcare Services industry average.
X
Value checks
We assess Livongo Health's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare Services industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare Services industry average (and greater than 0)? (1 check)
  5. Livongo Health has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Livongo Health expected to perform in the next 1 to 3 years based on estimates from 8 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
22%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Livongo Health expected to grow at an attractive rate?
  • Unable to compare Livongo Health's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Livongo Health's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • Livongo Health's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGS:LVGO Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGS:LVGO Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts 22%
NasdaqGS:LVGO Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 8 Analysts 38.6%
United States of America Healthcare Services Industry Earnings Growth Rate Market Cap Weighted Average 23.8%
United States of America Healthcare Services Industry Revenue Growth Rate Market Cap Weighted Average 14.4%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 12.2%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGS:LVGO Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGS:LVGO Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2022-12-31 645 2
2021-12-31 443 -18 -35 8
2020-12-31 284 -17 -55 8
2020-04-03
NasdaqGS:LVGO Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 170 -59 -55
2019-09-30 141 -67 -62
2019-06-30 113 -60 -52
2019-03-31 88 -50 -44
2018-12-31 68 -33 -34
2017-12-31 31 -16 -17

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Livongo Health is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Livongo Health's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGS:LVGO Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below

All data from Livongo Health Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:LVGO Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2022-12-31
2021-12-31 -0.34 -0.28 -0.42 3.00
2020-12-31 -0.49 -0.47 -0.52 3.00
2020-04-03
NasdaqGS:LVGO Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -1.09
2019-09-30 -1.93
2019-06-30 -2.95
2019-03-31 -2.59
2018-12-31 -2.02
2017-12-31 -1.18

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Livongo Health is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Livongo Health's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Livongo Health has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Livongo Health performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Livongo Health's growth in the last year to its industry (Healthcare Services).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Livongo Health does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Livongo Health's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Livongo Health's 1-year growth to the US Healthcare Services industry average as it is not currently profitable.
Earnings and Revenue History
Livongo Health's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Livongo Health Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:LVGO Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 170.20 -55.37 133.24 49.81
2019-09-30 140.81 -61.52 118.61 45.46
2019-06-30 112.94 -52.35 98.33 34.47
2019-03-31 88.03 -44.29 78.64 29.71
2018-12-31 68.43 -33.54 59.14 24.86
2017-12-31 30.85 -17.00 27.55 12.03

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Livongo Health has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Livongo Health has efficiently used its assets last year compared to the US Healthcare Services industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Livongo Health improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Livongo Health's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare Services industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Livongo Health has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Livongo Health's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Livongo Health's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Livongo Health is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Livongo Health's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Livongo Health's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Livongo Health has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Livongo Health Company Filings, last reported 3 months ago.

NasdaqGS:LVGO Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 507.36 0.00 391.94
2019-09-30 501.33 0.00 400.00
2019-06-30 127.54 0.00 38.43
2019-03-31 136.00 0.00 57.41
2018-12-31 145.12 0.00 109.65
2017-12-31 65.61 0.00 61.37
  • Livongo Health has no debt.
  • Livongo Health has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Livongo Health has sufficient cash runway for more than 3 years based on current free cash flow.
  • Livongo Health has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 54.2% each year.
X
Financial health checks
We assess Livongo Health's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Livongo Health has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Livongo Health's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Livongo Health dividends. Estimated to be 0% next year.
If you bought $2,000 of Livongo Health shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Livongo Health's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Livongo Health's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGS:LVGO Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
Global Healthcare Services Industry Average Dividend Yield Market Cap Weighted Average of 29 Stocks 0.7%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1941 Stocks 3.1%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 2%
United States of America Top 25% Dividend Yield 75th Percentile 5.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGS:LVGO Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2022-12-31 0.00 1.00
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2020-04-03

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Livongo Health has not reported any payouts.
  • Unable to verify if Livongo Health's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Livongo Health's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Livongo Health has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Livongo Health's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess Livongo Health's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Livongo Health afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Livongo Health has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Livongo Health's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Zane Burke
AGE 53
TENURE AS CEO 1.2 years
CEO Bio

Mr. Zane M. Burke serves as Chief Executive Officer at Livongo Health, Inc. since February 2019 and serves as its Director since April 2019. Mr. Burke served as the President of Cerner Corporation since September 2013 until November 2, 2018. Mr. Burke served as an Executive Vice President of Client Organization at Cerner Corporation since July 2011 until September 2013 and served as its Executive Vice President since May 13, 2011. Mr. Burke served as an Senior Vice President of Healthe Leadership at Cerner Corporation until May 13, 2011. Mr. Burke served as Senior Vice President of Employer & Government at Cerner Corp. He joined Cerner Corp. in September 1996 as U.S. Corporate Controller. Since that time, Mr. Burke has held several positions in the finance organization including Corporate Controller and Vice President of Finance and was promoted to Vice President in 2000, President of Cerner West in January 2002 and Senior Vice President of National Alignment in 2006. Prior to Cerner Corp., Mr. Burke was with KPMG LLP for six years. In 2007, he was named the U.S. general manager for client relationships. In 2009, Healthe Services was added to his responsibilities. Prior to Cerner, he worked at the accounting firm Klynveld Peat Marwick Goerdeler (KPMG) for six years, where Cerner was one of his clients. Mr. Burke Earned his Bachelor's Degree in Accounting and an MBA from Kansas State University. He is a certified Public Accountant.

CEO Compensation
  • Insufficient data for Zane to compare compensation growth.
  • Insufficient data for Zane to establish whether their remuneration is reasonable compared to companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Livongo Health management team in years:

1.8
Average Tenure
53
Average Age
  • The average tenure for the Livongo Health management team is less than 2 years, this suggests a new team.
Management Team

Glen Tullman

TITLE
Founder & Executive Chairman
COMPENSATION
$3M
AGE
59

Jennifer Schneider

TITLE
President
COMPENSATION
$1M
AGE
44
TENURE
1.3 yrs

Jim Pursley

TITLE
Chief Commercial Officer
COMPENSATION
$744K
AGE
40
TENURE
6 yrs

Zane Burke

TITLE
CEO & Director
AGE
53
TENURE
1.2 yrs

Lee Shapiro

TITLE
Chief Financial Officer
AGE
63
TENURE
1.3 yrs

Karl Greiter

TITLE
Senior Vice President of Operations
TENURE
2.3 yrs

Dave Engberg

TITLE
Chief Technology Officer
TENURE
3.6 yrs

Alex Hughes

TITLE
VP of Investor Relations

Erica Palsis

TITLE
General Counsel
TENURE
1.3 yrs

Neal Welch

TITLE
Vice President of Sales
TENURE
6.5 yrs
Board of Directors Tenure

Average tenure and age of the Livongo Health board of directors in years:

3
Average Tenure
59
Average Age
  • The tenure for the Livongo Health board of directors is about average.
Board of Directors

Zane Burke

TITLE
CEO & Director
AGE
53
TENURE
1 yrs

Hemant Taneja

TITLE
Independent Director
TENURE
6 yrs

Glen Tullman

TITLE
Founder & Executive Chairman
COMPENSATION
$3M
AGE
59
TENURE
1.2 yrs

Phil Green

TITLE
Lead Independent Director
AGE
68

Karen Daniel

TITLE
Independent Director
AGE
61
TENURE
0.9 yrs

Dave Hartwig

TITLE
Board Observer
AGE
46
TENURE
3.8 yrs

Tim Anderson

TITLE
Board Observer
TENURE
3.8 yrs

Chris Bischoff

TITLE
Independent Director
AGE
46
TENURE
2 yrs

Nagraj Kashyap

TITLE
Board Observer
TENURE
3 yrs

Jeff Vinik

TITLE
Board Observer
AGE
59
TENURE
3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
01. Aug 19 Buy General Catalyst Partners Company 29. Jul 19 29. Jul 19 2,678,571 $28.00 $74,999,988
18. Nov 19 Buy Christopher Bischoff Individual 18. Nov 19 18. Nov 19 4,000 $25.48 $101,920
31. Jul 19 Buy Kinnevik AB Company 29. Jul 19 29. Jul 19 3,141,795 $28.00 $87,970,260
X
Management checks
We assess Livongo Health's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Livongo Health has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Livongo Health, Inc. provides an integrated suite of solutions for the healthcare industry in North America. It solutions promote health behavior change based on real-time data capture supported by intuitive devices and insights driven by data science. The company offers a platform that provides cellular-connected devices, supplies, informed coaching, data science-enabled insights, and facilitates access to medications. Its products include Livongo for Diabetes, Livongo for Hypertension, Livongo for Prediabetes and Weight Management, and Livongo for Behavioral Health by myStrength. The company was formerly known as EosHealth, Inc. and changed its name to Livongo Health, Inc. in 2014. Livongo Health, Inc. was incorporated in 2008 and is headquartered in Mountain View, California.

Details
Name: Livongo Health, Inc.
LVGO
Exchange: NasdaqGS
Founded: 2008
$2,509,316,160
96,032,000
Website: http://www.livongo.com
Address: Livongo Health, Inc.
150 West Evelyn Avenue,
Suite 150,
Mountain View,
California, 94041,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS LVGO Common Stock Nasdaq Global Select US USD 25. Jul 2019
Number of employees
Current staff
Staff numbers
615
Livongo Health employees.
Industry
Health Care Technology
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/03 05:05
End of day share price update: 2020/04/02 00:00
Last estimates confirmation: 2020/04/03
Last earnings filing: 2020/03/24
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.